Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of eptacog beta for hemostatic control during major elective surgery in hemophilia A or B with inhibitors
2022-004132-25Phase 3
- Sponsor
- LFB Group
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor VIIa-jncw in hemophilia A and hemophilia B (HB), sponsored by LFB Group. Primary endpoint: Proportion of successfully treated major procedures.
02
Drugs
coagulation factor VIIa-jncw
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2022-004132-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004132-25.